1. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
- Author
-
Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, and Memmos D
- Subjects
- Drug Therapy, Combination, Female, Humans, Long-Term Care, Male, Middle Aged, Prednisolone therapeutic use, Recurrence, Treatment Outcome, Cyclosporine therapeutic use, Glomerulonephritis, Membranous complications, Glomerulonephritis, Membranous drug therapy, Immunosuppressive Agents therapeutic use, Nephrotic Syndrome complications, Nephrotic Syndrome drug therapy
- Abstract
Background: Cyclosporine A (CyA) has been shown to be effective in membranous nephropathy (MN). However, the optimal dose and the duration of treatment remain controversial issues. We evaluated the efficacy of low-dose CyA alone or combined with corticosteroids as induction and long-term treatment for nephrotic patients with MN., Methods: In the first part of the study, 51 nephrotic patients with MN were treated either with CyA and prednisolone (n=31) or CyA alone (n=20) for 12 months. Patients who responded with complete remission (CR) or partial remission (PR) were placed on long-term treatment with lower doses of CyA and prednisolone or CyA alone. The mean follow-up of the second part of the study was 26+/-16 months and 18+/-7 months, respectively., Results: After 12 months of treatment, 26 patients in the combination group and 17 patients in the monotherapy group had a CR or PR of proteinuria (P=NS). Renal function was unchanged in the two groups. During long-term treatment relapses were more frequent in the monotherapy group (47 vs 15%, P<0.05). Daily CyA dose was higher in non-relapsers in both groups (combination 1.4+/-0.5 vs 1.0+/-0.3 mg/kg, P<0.001, monotherapy 1.5+/-0.4 vs 1.1+/-0.2 mg/kg, P<0.003). Relapsers in both groups had lower CyA trough levels (72+/-48 ng/ml) compared with non-relapsers (194+/-80 ng/ml) (P<0.03). Renal function and proteinuria remained stable during the follow-up., Conclusion: This study suggests that 12-month therapy with CyA (+/-prednisolone) is effective in inducing remission in most nephrotic patients with MN and well-preserved renal function. Longer treatment with lower doses is a useful approach to maintain remission. Relapses occur more frequently in the monotherapy group and usually are associated with CyA trough levels<100 ng/ml.
- Published
- 2006
- Full Text
- View/download PDF